NeoGenomics Inc. Announces Partnership with Lilly for Lung Cancer Sponsored Testing Program Utilizing the NeoTYPE(R) DNA and RNA Assay
FT. MYERS, FL / ACCESSWIRE / April 25, 2022 / NeoGenomics, Inc.
(NASDAQ:NEO), a leading provider of cancer-focused genetic testing
services and global oncology contract research services, announced today
that they are partnering with Eli Lilly and Company on a sponsored
testing program for eligible patients with metastatic non-small cell
lung cancer (NSCLC) at no cost.
More info >> |